Saama automates key clinical development and commercialization processes using AI, Generative AI, and advanced analytics — accelerating your time to market.
Saama automates key clinical development and commercialization processes using AI, Generative AI, and advanced analytics — accelerating your time to market.
Faster Data
Discovery
Patient Review
Savings
Transforming the FPI-to-Submission corridor with Responsible AI & Automation across all five functional domains of clinical trials
Per-Trial AI Savings
LPLV to Submission Compression
Productivity Gain
Per-Trial AI Savings
LPLV to Submission Compression
Productivity Gain
50%–70% of trial spend is concentrated in five optimizable areas — yet most sponsors treat it as fixed.
Saama clients recover 15%–25% of compressible spend by applying AI-driven automation across data review, monitoring, and submission workflows — without touching fixed passthroughs.
LPLV-to-submission averages 20–24 weeks. Every extra week is budget burned and a patient waiting.
Automated data cleaning, lock readiness dashboards, and continuous signal detection compress the LPLV-to-lock window by 6–8 weeks — getting submissions out faster and teams off-trial sooner.
8–12 weeks post-lock, 30%–40% rework — because quality checks happen too late in the process.
Continuous quality checks running throughout the trial — not just at lock — reduce post-lock rework by up to 60% and cut statistical review cycles from weeks to days.
CRA turnover at 22%. AI workload growing 20% annually. The math doesn’t work without automation.
Saama’s AI agents automate up to 70% of routine monitoring tasks — SDV, source data review, query management — so CRAs spend time on sites, not screens. Lower burden, lower attrition.
6–9 months to first patient. 10%–15% of budget spent before a single data point is collected.
Digitized protocol-to-site packages and AI-assisted regulatory submission cut start-up timelines by 8–12 weeks, preserving $1M–$3M in pre-enrollment budget on a typical Phase II.
Most amendments are preventable. Each one costs $450K–$900K and disrupts every active site.
Protocol optimization at design time reduces amendment rate by 30%–40% — eliminating an average of $450K–$900K in per-amendment costs and the site disruption that follows.
From data origin to submission. Each domain carries its own workforce load, technology debt, and process latency.
10%–15%
$5M–$7.5M
$2M–$3.5M
10%–15%
$5M–$7.5M
$2M–$3.5M
20%–25%
$10M–$12.5M
$5M–$6.75M
5%–8%
$2.5M–$4M
$1.25M–$2.25M
8%–15%
$4M–$7.5M
$1.5M–$4M
8%–12%
$4M –
$6M
$1.5M – $3M
From data origin to submission. Each domain carries its own workforce load, technology debt, and process latency.
Budget Share:
As-Is:
To-Be:
Budget Share:
As-Is:
To-Be:
Budget Share:
As-Is:
To-Be:
Budget Share:
As-Is:
To-Be:
Budget Share:
As-Is:
To-Be:
Budget Share:
As-Is:
To-Be:
Budget Share:
As-Is:
To-Be:
A single, real-time view of study, country, and site-level start-up activities with automatically tracked milestones, surfacing bottlenecks before they delay.
Budget Share:
As-Is:
To-Be:
Automated data review, cleaning, and reconciliation that flags discrepancies and generates queries as data is collected, keeping the database clean through to.
Budget Share:
As-Is:
To-Be:
Role-specific, real-time visibility across operational, clinical, and financial sources, so teams can prioritize site activity and act on risks instead of chasing reports.
Budget Share:
As-Is:
To-Be:
Continuous monitoring of data and processes across the trial, with predictive risk assessments and recommendations that de-risk operationsin real time.
Budget Share:
As-Is:
To-Be:
Centralized patient data with real-time AI that predicts patient behavior, tracks progress, and accelerates clinical signal discovery.
Budget Share:
As-Is:
To-Be:
AI-automated dataset transformation and mapping that simplifies and accelerates regulatory submissions with improved accuracy and consistency.
Budget Share:
As-Is:
To-Be:

Chief Efficiency Officer
We didn't take a general AI and apply it to clinical trials. We built clinical AI from day one — and spent a decade perfecting it. That gap doesn't close overnight
Backed by 4100+, global research citations, 99+ publications, and an in-house research lab that competitors simply don’t have.












Saama’s AI platform delivers measurable, documented results across every stage of clinical development. These aren’t projections — they’re proof.
Faster Data Discovery
reduction in time to data discovery
Hours Saved
Patient Review Savings
Faster Document Drafting
Therapeutic Areas
Research Citations

Chief Efficiency Officer
Saama has over a decade of experience developing and training AI models for life sciences that can be used out-of-the-box. Other companies are just beginning this research. By partnering with Saama, you are ahead of the curve.
In-House Dedicated AI Researchers — our lab has spent a decade building, training and evolving AI/ML models specifically for life sciences.
Trained AI/ML Models
Our AI research lab has spent a decade building, training and evolving AI/ML models specifically for life sciences.
Publications
Saama’s AI experts have had work published in over 20 publications globally.
Years of AI Research
Patents
Our researchers have secured 8 patents for their work.
Therapeutic Areas
Clinical Studies
Most AI projects in clinical development never leave pilot. In this live webinar, Saama’s AI research team breaks down the structural barriers — and how agentic, modular AI is built to overcome them. Watch now, available on-demand.
Questions about Data Hub, SDQ, Patient Insights, or our AI Document Generator? Saama Llama has the answers.
By admin
According to the Tufts Center for the Study of Drug Development, the average clinical trial can take 7–10 years from discovery to approval, and delays…
By admin
Clinical data review has always been one of those parts of a trial that takes more time than anyone expects. An industry report by NIH…
By admin
Let’s take a minute to think about what it really takes to bring a new medicine to patients- it’s a massive, critical effort, but too…